Tenderwize
Back to tender search

Octreotide (ATC: H01CB02 - Retard Formulations)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Feb 27, 2027 · 194 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Octreotid (ATC: H01CB02 - retardierte Darreichungsformen)

50/100

Opportunity Score

PromisingLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

30 / 100

Risk factors

Contracts may be terminated early if AOK awards exclusive contracts for the same active substance during the term.

Open-house model with no exclusivity means no commitment from AOK to purchase any quantity.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Strong opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Supply of Octreotide (ATC: H01CB02 - retard formulations) pharmaceutical products
Show full summary

Open-house model for non-exclusive discount agreements (Rabattverträge) under §130a Abs.8 SGB V for Octreotide (retard formulations) with AOK Sachsen-Anhalt. Any eligible pharmaceutical company can join at any time until the deadline. No estimated value provided. Not a traditional public procurement.

Risks

Contracts may be terminated early if AOK awards exclusive contracts for the same active substance during the term.

Open-house model with no exclusivity means no commitment from AOK to purchase any quantity.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Non-exclusive discount agreement under §130a Abs.8 SGB V
  • Open-house model: contract can be concluded at any time until deadline

Administrative

  • Uniform contract terms for all participants

Requirements may be incomplete.

Award Criteria

Lot 1

Open-house: any qualified supplier gets contract

Buyer

Location

Magdeburg, DEU

Buyer profile

Open profile

Identifier

DE258393558

Activity

Health

Lots (1)

LOT-0001

Octreotide (ATC: H01CB02 - Retard Formulations)

Non-exclusive discount agreement for Octreotide retard formulations, open to all qualified pharmaceutical companies under uniform terms. Contract duration max 24 months, ending 30.04.2027. Early termination possible if AOK awards exclusive contracts.

SuppliesEU fundedElectronic submission

Location

DEE03, Germany

Duration

2 YEAR

Category

Pharmaceutical products

Award Criteria

Open-house: any qualified supplier gets contract

Deadline

Deadline Feb 27, 2027

Procurement Details

Publication date
19 Mar 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
181177-2025

Documents (1)

Similar tenders